Tear lipocalin muteins binding IL-4 R alpha
The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
1. A method of binding Interleukin 4 (IL 4) receptor alpha in a subject, comprising the step of administrating a mutein of human tear lipocalin having binding affinity to IL 4 receptor alpha to the subject, wherein with respect to the amino acid sequence of mature human tear lipocalin said mutein comprises a set of amino acid substitutions selected from the group consisting of:
(1) Arg 26→Ser; Asn 32→Tyr; Met 55→Leu; Leu 56→Gln; and Ser 58→Lys;
(2) Arg 26→Pro; Asn 32→Tyr; Glu 34→Ser; Met 55→Ala; Leu 56→Gln; and Glu 63→Lys;
(3) Arg 26→Leu; Asn 32→Phe; Glu 34→Trp; Met 55→Ala; Ser 58→Ile; and Glu 63→Ser;
(4) Arg 26→Ser; Asn 32→Tyr; Glu 34→Val; Met 55→Ala; Leu 56→Ala; Ser 58→Ile; and Glu 63→Ser;
(5) Arg 26→Ser; Asn 32→Val; Glu 34→Asn; Met 55→Ala; Leu 56→Gln; Ser 58→Lys; and Glu 63→Lys;
(6) Arg 26→Asn; Asn 32→Lys; Glu 34→Asp; Met 55→Ala; Leu 56→His; Ser 58→Arg; and Glu 63→Gln;
(7) Arg 26→Tyr; Asn 32→Tyr; Glu 34→His; Met 55→Ala; Leu 56→His; Ser 58→Ala; and Glu 63→Lys;
(8) Arg 26→Lys; Asn 32→Tyr; Glu 34→Arg; Met 55→Ala; Leu 56→Lys; Ser 58→Asn; and Glu 63→Pro; and
(9) Arg 26→Glu; Asn 32→His; Glu 34→Gly; Met 55→Ala; Leu 56→Met; Ser 58→Leu; and Glu 63→Lys.
2. A pharmaceutical composition comprising a mutein of human tear lipocalin a mutein of human tear lipocalin having binding affinity to IL 4 receptor alpha, wherein with respect to the amino acid sequence of mature human tear lipocalin said mutein comprises a set of amino acid substitutions selected from the group consisting of:
(1) Arg 26→Ser; Asn 32→Tyr; Met 55→Leu; Leu 56→Gln; and Ser 58→Lys;
(2) Arg 26→Pro; Asn 32→Tyr; Glu 34→Ser; Met 55→Ala; Leu 56→Gln; and Glu 63→Lys;
(3) Arg 26→Leu; Asn 32→Phe; Glu 34→Trp; Met 55→Ala; Ser 58→Ile; and Glu 63→Ser;
(4) Arg 26→Ser; Asn 32→Tyr; Glu 34→Val; Met 55→Ala; Leu 56→Ala; Ser 58→Ile; and Glu 63→Ser;
(5) Arg 26→Ser; Asn 32→Val; Glu 34→Asn; Met 55→Ala; Leu 56→Gln; Ser 58→Lys; and Glu 63→Lys;
(6) Arg 26→Asn; Asn 32→Lys; Glu 34→Asp; Met 55→Ala; Leu 56→His; Ser 58→Arg; and Glu 63→Gln;
(7) Arg 26→Tyr; Asn 32→Tyr; Glu 34→His; Met 55→Ala; Leu 56→His; Ser 58→Ala; and Glu 63→Lys;
(8) Arg 26→Lys; Asn 32→Tyr; Glu 34→Arg; Met 55→Ala; Leu 56→Lys; Ser 58→Asn; and Glu 63→Pro; and
(9) Arg 26→Glu; Asn 32→His; Glu 34→Gly; Met 55→Ala; Leu 56→Met; Ser 58→Leu; and Glu 63→Lys;
and a pharmaceutically acceptable excipient.
3. A mutein of human tear lipocalin having binding affinity to IL 4 receptor alpha, wherein with respect to the amino acid sequence of mature human tear lipocalin said mutein comprises a set of amino acid substitutions selected from the group consisting of:
(1) Arg 26→Ser, Met 55→Leu, Ser 58→Lys;
(2) Arg 26→Pro and Glu 34→Ser;
(3) Arg 26→Pro and Met 55→Ala;
(4) Arg 26→Ser and Glu 34→Val;
(5) Arg 26→Leu, Glu 34→Trp and Met 55→Ala;
(6) Arg 26→Leu, Glu 34→Trp and Ser 58→Ile;
(7) Arg 26→Ser, Glu 34→Asn, Met 55→Ala, and Ser 58→Lys;
(8) Arg 26→Asn and Glu 34→Asp;
(9) Arg 26→Asn and Met 55→Ala;
(10) Arg 26→Tyr, Glu 34→His and Met 55→Ala;
(11) Arg 26→Tyr, Glu 34→His and Ser 58→Ala;
(12) Arg 26→Lys, Glu 34→Arg and Met 55→Ala;
(13) Arg 26→Lys, Glu 34→Arg and Ser 58 Asn;
(14) Arg 26→Glu, Glu 34→Arg and Met 55→Ala; and
(15) Arg 26→Glu, Glu 34→Arg and Ser 58 Leu.
4. The lipocalin mutein according to claim 3 , wherein the lipocalin mutein is fused at its N-terminus and/or its C-terminus to a fusion partner which is a protein, or a protein domain or a peptide.
5. The lipocalin mutein according to claim 3 , wherein the mutein is conjugated to a compound that extends the serum half-life of the mutein.
6. A nucleic acid molecule comprising a nucleotide sequence encoding the lipocalin mutein according to claim 3 .
7. An isolated host cell containing a nucleic acid molecule of claim 6 .